Compare Immunovant Inc. Common Stock (IMVT) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Remitly Global Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.5 (market cap $6.25B), while Remitly Global Inc trades at $24.17 (market cap $4.98B). The key difference: Immunovant Inc. Common Stock is the larger of the two by market cap, and Remitly Global Inc is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and Remitly Global Inc for 53 Days on average.
| IMVT | RELY | |
|---|---|---|
Market Cap | $6.25B | $4.98B |
Volume | 1,755,411 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $44.96 | $26.92 |
52-Week Low | $17.03 | $12.20 |
Typical Hold Time | 1 Days | 53 Days |
Enterprise Value | $5.35B | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RELY trades at $23.675, up 3.25% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats. Revenue surged to $1.64 billion in 2025, with net income turning positive at $67.93 million, reflecting a significant improvement in profitability. Recent news highlights partnerships, such as with Etsy, and strong analyst consensus favoring the stock.
The outlook for RELY is positive, driven by robust revenue growth, expanding margins, and a favorable analyst consensus with a $30.50 price target. Key risks include competitive pressures in fintech and reliance on sustained customer acquisition, but institutional interest and insider holdings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
